(Adnkronos) - “Elacestrant è un nuovo farmaco, un anti-ormonale, che agisce inibendo la funzionalità del recettore estrogenico anche quando si verificano dei meccanismi di resistenza”. Lo ha detto Valentina Guarneri, professore ordinario di Oncologia presso l’Università di Padova,, a margine di un corso di aggiornamento tenutosi a Roma sul carcinoma mammario Er+/Her2 - avanzato o metastatico con mutazioni Esr1.
Category
🗞
NewsTranscript
00:00Elastestrand is a new drug, a new antihormonal that belongs to the category of oral SERDs,
00:11which stands for selective degradators of the estrogen receptor.
00:15In practice, it acts by inhibiting the function of the estrogen receptor
00:20even when resistance mechanisms have been verified.
00:24Yes, SER1 is a mutation that arises as a resistance phenomenon
00:28under the inhibition of hormonal therapy,
00:32so patients who have this mutation have a lower response to traditional hormonal therapies
00:39but a better response to elastestrands.
00:41This therapy acts by antagonizing the receptor, inhibiting it or in the presence of this mutation.
00:47Certainly, liquid biopsy offers the possibility of measuring the eventual emergence of mutations
00:53that can be used for the selection of treatments.
00:56The fact of being able to use liquid biopsy also allows a serialized assessment over time,
01:02which is perhaps more difficult at the tissue level
01:05because it involves a biopsy that is more invasive as a method.